IE
CGTX icon

Israel Englander’s Cognition Therapeutics CGTX Stock Holding History

Israel Englander’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,657
Closed -$87.3K – 5786
2025
Q4 		$87.3K Sell
64,657
-495,896
-88% -$805K ﹤0.01% 5651
2025
Q3 		$757K Buy
+560,553
New +$764K ﹤0.01% 4824
2024
Q3 		– Sell
-13,624
Closed -$22.6K – 6132
2024
Q2 		$22.6K Buy
+13,624
New +$27.2K ﹤0.01% 5522
2022
Q2 		– Sell
-14,536
Closed -$39K – 7016
2022
Q1 		$39K Sell
14,536
-41,883
-74% -$161K ﹤0.01% 6464
2021
Q4 		$357K Buy
+56,419
New +$550K ﹤0.01% 5357

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Israel Englander's CGTX Position: Q1 2026 in Review

Israel Englander sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 64,657 shares — an estimated $87.3K sold.

Israel Englander first reported a position in CGTX in Q4 2021 and held it in 5 quarters. The position peaked at $757K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Israel Englander reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Israel Englander sold 64,657 Cognition Therapeutics shares in Q1 2026, an estimated $87.3K.
  • Israel Englander first reported a position in Cognition Therapeutics in Q4 2021 and held it in 5 quarters.
  • Israel Englander's Cognition Therapeutics position peaked at $757K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.